Clinical Trial Update: Ketoconazole in Treating Participants With Ongoing EGFR Inhibitor-Induced Rash [EARLY_Phase 1]

View source ↗

Summary

A completed early-phase 1 trial evaluating ketoconazole to treat EGFR inhibitor–induced rash in cancer patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• Ketoconazole (Ketoconazole)

Snippet

Sponsor: Mayo Clinic | Conditions: Malignant Neoplasm | EARLY_Phase 1 | Status: COMPLETED